OptimizeRx Corporation (OPRX)
| Market Cap | 97.39M -47.9% |
| Revenue (ttm) | 107.35M +13.8% |
| Net Income | 6.84M |
| EPS | 0.36 |
| Shares Out | 18.77M |
| PE Ratio | 14.59 |
| Forward PE | 5.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 528,524 |
| Open | 5.10 |
| Previous Close | 5.10 |
| Day's Range | 5.00 - 5.38 |
| 52-Week Range | 4.57 - 22.25 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+121.58%) |
| Earnings Date | May 12, 2026 |
About OPRX
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OPRX stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 121.58% from the latest price.
News
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastruc...
OptimizeRx price target lowered to $11 from $20 at Lake Street
Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $20 and keeps a Buy rating on the shares. While “disappointed” with the company’s lowered revenue guidance,…
OptimizeRx price target lowered to $10 from $11 at B. Riley
B. Riley lowered the firm’s price target on OptimizeRx (OPRX) to $10 from $11 and keeps a Buy rating on the shares. The underlying drivers of the second consecutive guidance…
OptimizeRx price target lowered to $7 from $10 at Stephens
Stephens lowered the firm’s price target on OptimizeRx (OPRX) to $7 from $10 and keeps an Equal Weight rating on the shares. OptimizeRx reduced revenue guidance by 13% based on…
OptimizeRx price target lowered to $14 from $17 at Stifel
Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $14 from $17 and keeps a Buy rating on the shares.
OptimizeRx Q1 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life scien...
OptimizeRx reports Q1 EPS 14c, consensus 0c
Reports Q1 revenue $18.94M, consensus $18.35M. Stephen Silvestro, OptimizeRx (OPRX) CEO commented, “We delivered a solid start to 2026, exceeding consensus for the quarter, reinforcing the strength an...
OptimizeRx cuts FY26 revenue view to $95M-$100M from $109M-$114M
Consensus $111.44M. Backs FY26 adjusted EBITDA view $21M-$25M. The company said, “Importantly, the long-term shift toward digital, data-driven engagement across life sciences remains firmly intact and...
OptimizeRx Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of $19.8M and adjusted EBITDA of $3.3M, with strong DAAP growth offset by macro headwinds and client-specific disruptions. 2026 revenue guidance was lowered to $95–$100M, but margin and EBITDA outlooks remain robust.
OptimizeRx Earnings release: Q1 2026
OptimizeRx released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
OptimizeRx Quarterly report: Q1 2026
OptimizeRx has published its Q1 2026 quarterly earnings report on May 12, 2026.
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance...
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Expands life sciences marketers' reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx's trusted EHR network for the first time Expands life sciences marketers' rea...
OptimizeRx Proxy statement: Proxy filing
OptimizeRx filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthca...
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency Microsoft Health & Life Sciences COO brings ...
OptimizeRx Slides: Corporate presentation
OptimizeRx has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
OptimizeRx trading halted, volatility trading pause
09:31 EST OptimizeRx (OPRX) trading halted, volatility trading pause
OptimizeRx price target lowered to $20 from $24 at Lake Street
Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $20 from $24 and keeps a Buy rating on the shares. While “disappointed” with the lowered revenue outlook for…
OptimizeRx price target lowered to $11 from $28 at B. Riley
B. Riley analyst Anderson Schock lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $28 and keeps a Buy rating on the shares. The firm views the company’s…
OptimizeRx price target lowered to $18 from $32 at Roth Capital
Roth Capital lowered the firm’s price target on OptimizeRx (OPRX) to $18 from $32 and keeps a Buy rating on the shares after it’s below-consensus revenue guidance. Revenue weakness rapidly…
OptimizeRx price target lowered to $17 from $21 at Stifel
Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $17 from $21 and keeps a Buy rating on the shares. A challenged environment is reflected in guidance, though this…
OptimizeRx price target lowered to $10 from $17 at Stephens
Stephens analyst Jeff Garro lowered the firm’s price target on OptimizeRx (OPRX) to $10 from $17 and keeps an Equal Weight rating on the shares despite a “big” Q4 EBITDA…